About BioBDx
BioBDx is a company based in Westford (United States) founded in 2004 was acquired by Pearson in August 2013. BioBDx has raised $30.41 million across 11 funding rounds from investors including Pearson, Sevin Rosen and Tullis Health Investors. BioBDx operates in a competitive market with competitors including Assurex Health, Genomind, Premier Biotech, Polaris Genomics and CNSDose, among others.
- Headquarter Westford, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biobehavioral Diagnostics Co
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of BioBDx
BioBDx has successfully raised a total of $30.41M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $500 thousand completed in February 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioBDx
BioBDx has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Pearson, Sevin Rosen and Tullis Health Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage US investments in technology and offline sectors are targeted.
|
Locked | Locked | Locked | |
|
Healthcare investments are made by Tullis Health Investors.
|
Locked | Locked | Locked | |
|
Provider of evidence-based learning products and solutions for learners and educators
|
Locked | Locked | Locked |
Investor details for BioBDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioBDx
Investment portfolio details for BioBDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioBDx
Detailed financials for BioBDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biobdx Comparisons
Peer comparison for BioBDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioBDx
BioBDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Assurex Health, Genomind, Premier Biotech, Polaris Genomics and CNSDose, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Personalized medication for neuropsychiatric conditions is guided by pharmacogenomics.
|
|
| Locked | Locked | Locked |
Genetic tests for personalized mental health treatments are developed.
|
|
| Locked | Locked | Locked |
Rapid drug testing solutions and lab services are provided.
|
|
| Locked | Locked | Locked |
Genomic-based diagnostics and therapeutics for neurological conditions are developed.
|
|
| Locked | Locked | Locked |
Pharmacogenomics tools for anti-depressant regimens are developed.
|
Detailed competitors of BioBDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biobdx
Complete news archive for BioBDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioBDx
BioBDx was founded in 2004 and raised its 1st funding round 3 years after it was founded.
BioBDx is headquartered in Westford, United States. It is registered at Westford, Massachusetts, United States.
BioBDx is a funded company, having raised a total of $30.41M across 11 funding rounds to date.
BioBehavioral Diagnostics (BioBDx) develops tools for the assessment of Attention deficit hyperactivity disorder (ADHD) symptoms. Its flagship product is the Quotient ADHD System, a tool that assesses ADHD symptoms by using advanced motion tracking technology to measure three core symptoms in the patient: hyperactivity, inattention and implusivity, while they complete a standardized test. It then uses proprietary algorithms to analyze and score patterns of motion, accuracy of the responses, and fluctuations in attention state. Quotient ADHD is currently approved by the US FDA. BioBDx was acquired by Pearson in August 2013.
BioBDx's top competitors include Assurex Health, Genomind and CNSDose.
BioBDx has 3 investors. Key investors include Pearson, Sevin Rosen, and Tullis Health Investors.